Literature DB >> 24812651

Clozapine in borderline personality disorder: a review of the evidence.

Anand Beri1, Jane Boydell.   

Abstract

BACKGROUND: Borderline personality disorder (BPD) is a serious mental disorder that is difficult to treat. Possible targets for pharmacotherapy include affective symptoms, cognitive disturbances, and impulsive, self-injurious behaviors. Although many of the medications tested for treatment of BPD have been demonstrated to be useful, no clear pharmacologic treatment has emerged. Clozapine is one of the medications that has been evaluated for the treatment of severe BPD. The aim of this review is to summarize the evidence examining the effectiveness of clozapine in the treatment of BPD.
METHODS: A comprehensive search of the health science databases PubMed, EMBASE, CINAHL, PsycINFO, Web of Science, Cochrane Library, and Google Scholar was performed for studies describing the use of clozapine in the treatment of BPD.
RESULTS: After the initial search, no randomized controlled trials evaluating the effectiveness of clozapine in BPD were identified. Therefore, case reports and case series were reviewed, with 12 articles selected for final review.
CONCLUSIONS: This review suggests that clozapine may be a beneficial treatment option for BPD especially in controlling symptom severity, psychotic symptoms, impulsivity, self-mutilation, number of days on enhanced observation, use of restraint, and overall functioning.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24812651

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  7 in total

1.  The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial.

Authors:  Mike J Crawford; Verity C Leeson; Rachel Evans; Barbara Barrett; Aisling McQuaid; Jack Cheshire; Rahil Sanatinia; Gary Lamph; Piyal Sen; Katina Anagnostakis; Louise Millard; Inti Qurashi; Fintan Larkin; Nusrat Husain; Paul Moran; Thomas R E Barnes; Carol Paton; Zoe Hoare; Marco Picchioni; Simon Gibbon
Journal:  Ther Adv Psychopharmacol       Date:  2022-04-29

2.  Effective and underprescribed: what about clozapine?

Authors:  Helge H O Müller
Journal:  Ment Illn       Date:  2017-10-19

3.  Switching bipolar disorder patients treated with clozapine to another antipsychotic medication: a mirror image study.

Authors:  Petru Ifteni; Andreea Teodorescu; Marius Alexandru Moga; Alina Mihaela Pascu; Roxana Steliana Miclaus
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-23       Impact factor: 2.570

4.  Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder.

Authors:  Geoffrey L Dickens; Catherine Frogley; Fiona Mason; Katina Anagnostakis; Marco M Picchioni
Journal:  Borderline Personal Disord Emot Dysregul       Date:  2016-10-07

5.  Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.

Authors:  Deanna L Kelly; Raymond C Love
Journal:  Ment Health Clin       Date:  2019-03-01

6.  Remission of Suicidal Ideation in Emotionally Unstable Personality Disorder with Flupenthixol.

Authors:  Daniel J Chivers; Mohammed Shaffiullah
Journal:  Case Rep Psychiatry       Date:  2022-01-13

7.  Second-generation antipsychotic use in borderline personality disorder: What are we targeting?

Authors:  Adrian Wasylyshen; Andrew M Williams
Journal:  Ment Health Clin       Date:  2016-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.